Acute Myocardial Infarction (AMI), Stable Angina, Unstable Angina
Conditions
Keywords
prospective cohort, multi-omics, artificial intelligence, risk prediction, precision medicine, acute myocardial infarction, lifespan cohort
Brief summary
This prospective cohort study aims to establish a lifespan cohort of myocardial infarction and build a standardized, multidimensional, and shareable disease-specific database by systematically integrating clinical phenotypes, multi-omics data, and longitudinal follow-up information. Based on artificial intelligence and multi-omics integration, the study further seeks to develop a precision prevention and control framework for acute myocardial infarction covering the full continuum from early risk warning and accurate diagnosis to individualized treatment and long-term risk management. The study will enroll adults aged 18 to 74 years, including two major populations: individuals at high risk of acute myocardial infarction, such as those with stable or unstable angina, and patients with confirmed acute myocardial infarction diagnosed according to the Fourth Universal Definition of Myocardial Infarction. Biospecimens, including venous blood, urine, and feces, will be collected, and participants will undergo standardized baseline assessment and follow-up. The primary outcome is all-cause mortality during follow-up. Secondary outcomes include cardiovascular death, recurrent myocardial infarction, readmission due to heart failure, revascularization, stroke, stent thrombosis, and severe bleeding. This study is expected to provide scientific evidence and technical support for precision prevention, diagnosis, treatment, and long-term management of myocardial infarction.
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
Age 18 to 74 years Diagnosed with stable angina, unstable angina, or acute myocardial infarction For acute myocardial infarction: symptom onset to hospital admission less than 24 hours, with patients undergoing emergency percutaneous coronary intervention prioritized Diagnosis of acute myocardial infarction according to the Fourth Universal Definition of Myocardial Infarction Willing to participate and able to provide written informed consent Able to complete baseline assessment, biospecimen collection, and long-term follow-up
Exclusion criteria
End-stage malignant tumor with expected survival of less than 1 year Severe hepatic or renal dysfunction (estimated glomerular filtration rate \<30 mL/min/1.73 m² or Child-Pugh class C) Active autoimmune disease or long-term use of immunosuppressive agents Pregnant or breastfeeding women Inability to provide informed consent or severe cognitive impairment Previous participation in another clinical study that may conflict with this project Any other condition considered by the investigators to make participation inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of all-cause mortality | From enrollment to the end of study follow-up, up to 5 years |
Secondary
| Measure | Time frame |
|---|---|
| Rate of cardiovascular death | From enrollment to the end of study follow-up, up to 5 years |
| Rate of recurrent myocardial infarction | From enrollment to the end of study follow-up, up to 5 years |
| Rate of readmission due to heart failure | From enrollment to the end of study follow-up, up to 5 years |
| Rate of target vessel or non-target vessel revascularization | From enrollment to the end of study follow-up, up to 5 years |
| Rate of stroke | From enrollment to the end of study follow-up, up to 5 years |
| Rate of definite or probable stent thrombosis | From enrollment to the end of study follow-up, up to 5 years |
| Rate of severe bleeding | From enrollment to the end of study follow-up, up to 5 years |
Countries
China
Contacts
Fuzhou University Affiliated Provincial Hospital